IL-23 promotes tumour incidence and growth
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Chronic inflammation has long been associated with increased incidence of malignancy and similarities in the regulatory mechanisms have been suggested for more than a century. Infiltration of innate immune cells, elevated activities of matrix metalloproteases and increased angiogenesis and vasculature density are a few examples of the similarities between chronic and tumour-associated inflammation. Conversely, the elimination of early malignant lesions by immune surveillance, which relies on the cytotoxic activity of tumour-infiltrating T cells or intra-epithelial lymphocytes, is thought to be rate-limiting for the risk to develop cancer. Here we show a molecular connection between the rise in tumour-associated inflammation and a lack of tumour immune surveillance. Expression of the heterodimeric cytokine interleukin (IL)-23, but not of its close relative IL-12, is increased in human tumours. Expression of these cytokines antagonistically regulates local inflammatory responses in the tumour microenvironment and infiltration of intra-epithelial lymphocytes. Whereas IL-12 promotes infiltration of cytotoxic T cells, IL-23 promotes inflammatory responses such as upregulation of the matrix metalloprotease MMP9, and increases angiogenesis but reduces CD8 T-cell infiltration. Genetic deletion or antibody-mediated elimination of IL-23 leads to increased infiltration of cytotoxic T cells into the transformed tissue, rendering a protective effect against chemically induced carcinogenesis. Finally, transplanted tumours are growth-restricted in hosts depleted for IL-23 or in IL-23-receptor-deficient mice. Although many strategies for immune therapy of cancer attempt to stimulate an immune response against solid tumours, infiltration of effector cells into the tumour tissue often appears to be a critical hurdle. We show that IL-23 is an important molecular link between tumour-promoting pro-inflammatory processes and the failure of the adaptive immune surveillance to infiltrate tumours.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IL-17 also induces proliferative signaling in keratinocytes through Act1, a major facet of its impact in psoriasis and perhaps also explaining its involvement in skin tumorigenesis”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Langowski et al., 2006
In the citing paper
“this pro-proliferative role likely contributes to the pathogenic effects of IL-17 in psoriasis, as well as potentially in skin cancer”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Langowski et al., 2006
In the citing paper
“In addition, as discussed above, IL-17 promotes proliferation of skin epithelial cells to promote tumorigenesis”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Langowski et al., 2006
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., & Weaver, C. T. (2005) · Nature Immunology · doi:10.1038/ni1254 · Cited by 4,742
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099
Self-citationInterleukin-12 and the regulation of innate resistance and adaptive immunity
Trinchieri, G. (2003) · Nature Reviews Immunology · doi:10.1038/nri1001 · Cited by 3,927
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Cua, D. J., Sherlock, J., Chen, Y., Murphy, C. A., Joyce, B., Seymour, B., Lucian, L., To, W., Kwan, S., Churakova, T., et al. (2003) · Nature · doi:10.1038/nature01355 · Cited by 2,906
Self-citationOppmann, B., Lesley, R., Blom, B., Timans, J. C., Xu, Y., Hunte, B., Vega, F., Yu, N., Wang, J., Singh, K., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00070-4 · Cited by 2,822
Self-citationMatrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797
Aggarwal, S., Ghilardi, N., Xie, M.-H., de Sauvage, F. J., & Gurney, A. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207577200 · Cited by 1,847
Cited by
Items 501–600 of 1,000
Interleukins and Cancer Immunotherapy
Yoshimoto, T., Morishima, N., Okumura, M., Chiba, Y., Xu, M., & Mizuguchi, J. (2009) · Immunotherapy · doi:10.2217/imt.09.46 · Cited by 36
Attiq, A., & Afzal, S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1255727 · Cited by 33
“Moreover, suppression of immune-surveillance modulating cell-mediated anti-tumour activities allows the cancer cell to evade the immune responses and proliferate without any check and balance (Langowski et al., 2006).”
BackgroundViral and cellular oncogenes promote immune evasion
Roetman, J. J., Apostolova, M. K. I., & Philip, M. (2022) · Oncogene · doi:10.1038/s41388-021-02145-1 · Cited by 34
“In the same model, co-expression of KRAS and MYC upregulated interleukin-23 (IL-23), which suppresses innate immune cells such as natural killer (NK) cells and reduces CTL infiltration [58, 59] (Fig.”
BackgroundAct1-ivating IL-17 inflammation
Hunter, C. A. (2007) · Nature Immunology · doi:10.1038/ni0307-232 · Cited by 33
Chang, H.-H., Young, S. H., Sinnett‐Smith, J. W., Chou, C. E. N., Moro, A., Hertzer, K. M., Hines, O. J., Rozengurt, E., & Eibl, G. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00417.2014 · Cited by 31
“cell-mediated immune surveillance (25, 38).”
Xu, X., Yang, C., Chen, J., Liu, J., Li, P., Shi, Y., & Yu, P.-W. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.03.144 · Cited by 33
High expression of Foxp3, IL-23p19 and survivin mRNA in colorectal carcinoma
Stanilov, N., Miteva, L. D., Mintchev, N., & Stanilova, S. A. (2008) · International Journal of Colorectal Disease · doi:10.1007/s00384-008-0588-8 · Cited by 31
Microbial deprivation, inflammation and cancer
von Hertzen, L. C., Joensuu, H., & Haahtela, T. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9284-1 · Cited by 33
IL-17A-producing T cells are associated with the progression of lung adenocarcinoma
Bao, Z., Lu, G., Cui, D., Yao, Y., Yang, G., & Zhou, J. (2016) · Oncology Reports · doi:10.3892/or.2016.4837 · Cited by 30
“IL-23 further induces the production of IL-17 by Th17 and γδT cells, and promotes tumor growth (22,57).”
BackgroundKim‐Schulze, S., Taback, B., & Kaufman, H. L. (2007) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2007.07.011 · Cited by 30
Targeting IL-23 in human diseases
D’Elios, M. M., Prete, G. D., & Amedei, A. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.497143 · Cited by 32
“In fact, although there are many studies [97,98,100-102] demonstrating the anti-tumor properties of IL-23, that elicit interest for possible use for cancer treatment [104,105], one has not to forget that emerging studies foresaw a possible role of IL-23 in carcinogenesis [106-108].”
BackgroundLocalization of IL-17+Foxp3+ T Cells in Esophageal Cancer
Huang, C., & Fu, Z. (2011) · Immunological Investigations · doi:10.3109/08820139.2011.555489 · Cited by 30
“Recent reports indicate that IL-17 may play potential roles in the development of cancer (Langowski et al., 2006; Kryczek et al., 2007) and serve as a prognostic marker of cancer (Zhang et al.”
BackgroundUemura, Y., Liu, T.-Y., Narita, Y., Suzuki, M., Nakatsuka, R., Araki, T., Matsumoto, M., Iwai, L. K., Hirosawa, N., Matsuoka, Y., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900873 · Cited by 30
“There is evidence suggesting the tumorigenic properties of IL-23 and IL-17 (28, 60, 61).”
BackgroundMethodThe Role of T-Helper 17 (Th17) Cells in Patients with Medulloblastoma
Zhou, P., Sha, H., & Zhu, J. (2010) · Journal of International Medical Research · doi:10.1177/147323001003800223 · Cited by 30
Role of Fungal Infections in Carcinogenesis and Cancer Development; A Literature Review
Hosseini, K., Ahangari, H., Chapeland‐Leclerc, F., Ruprich‐Robert, G., Tarhriz, V., & Dilmaghani, A. (2021) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2022.076 · Cited by 46
Sorrentino, C., Ciummo, S. L., D’Antonio, L., Fieni, C., Lanuti, P., Turdo, A., Todaro, M., & Carlo, E. D. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002966 · Cited by 29
Immune microenvironment of cervical cancer and the role of IL-2 in tumor promotion
Trujillo-Cirilo, L., Weiss‐Steider, B., Vargas-Ángeles, C. A., Corona-Ortega, M. T., & Rangel-Corona, R. (2023) · Cytokine · doi:10.1016/j.cyto.2023.156334 · Cited by 31
Breast tumor cells primed by endoplasmic reticulum stress remodel macrophage phenotype.
Cullen, S. J., Fatemie, S., & Ladiges, W. (2013) · Europe PMC (PubMed Central) · Cited by 31
How do Tumors Actively Escape from Host Immunosurveillance?
Wilczyński, J. R., & Duechler, M. (2010) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-010-0102-1 · Cited by 33
Kumar, A., Dorairaj, S. K., Prabhakaran, V. C., Prakash, D. R., & Chakraborty, S. (2007) · Genomics · doi:10.1016/j.ygeno.2007.07.008 · Cited by 31
“[29] have recently demonstrated that expression of the heterodimeric cytokine IL23 is increased in human tumors.”
BackgroundInterleukin-27 Signaling Promotes Immunity against Endogenously Arising Murine Tumors
Natividad, K. D. T., Junankar, S. R., Redzwan, N. M., Nair, R., Wirasinha, R. C., King, C., Brink, R. A., Swarbrick, A., & Batten, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057469 · Cited by 28
“ment, leading to the current consensus, that IL-23 is in fact protumorigenic [32,33].”
BackgroundInnate lymphoid cells in intestinal cancer development
Atreya, I., Kindermann, M., & Wirtz, S. J. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.02.001 · Cited by 30
Polak-Szczybyło, E., & Tabarkiewicz, J. (2022) · Nutrients · doi:10.3390/nu14030643 · Cited by 30
Is Candida albicans an opportunistic oncogenic pathogen?
Sultan, A. S., Theofilou, V. I., Alfaifi, A. A., Montelongo‐Jauregui, D., & Jabra‐Rizk, M. A. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010413 · Cited by 28
“However, other cytokines of the Th17 family, such as IL-23, promote angiogenesis and tumor growth [29].”
BackgroundIida, T., Iwahashi, M., Katsuda, M., Ishida, K., Nakamori, M., Nakamura, M., Naka, T., Ojima, T., Ueda, K., Hayata, K., et al. (2013) · Oncology Reports · doi:10.3892/or.2013.2911 · Cited by 28
ILC regulation of T cell responses in inflammatory diseases and cancer
Warner, K., & Ohashi, P. S. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101284 · Cited by 29
NF-κB Fans the Flames of Lung Carcinogenesis
Wong, K., Jacks, T., & Dranoff, G. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0042 · Cited by 28
Goc, J., Hepworth, M. R., & Sonnenberg, G. F. (2015) · International Immunology · doi:10.1093/intimm/dxv056 · Cited by 29
Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors
Wilczyński, J. R., & Nowak, M. (2022) · Experientia supplementum · doi:10.1007/978-3-030-91311-3_1 · Cited by 33
IL-12 and IL-23 Affect Photocarcinogenesis Differently
Jantschitsch, C., Weichenthal, M., Proksch, E., Schwarz, T., & Schwarz, A. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.469 · Cited by 27
“With regard to carcinomas in murine skin, it has been shown that IL-23 promotes tumor formation via favoring a proinflammatory environment and reducing the amount of infiltrating CD8þ cytotoxic T cells (Langowski et al., 2006).”
BackgroundControversies in mucosal healing in ulcerative colitis
Kane, S. V., Lu, F., Kornbluth, A. A., Awais, D., & Higgins, P. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20875 · Cited by 27
Poland, M., ten Klooster, J. P., Wang, Z., Pieters, R. H. H., Boekschoten, M. V., Witkamp, R. F., & Meijerink, J. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.09.012 · Cited by 28
Oncostatin M is overexpressed in skin squamous-cell carcinoma and promotes tumor progression
Simonneau, M., Frouin, É., Huguier, V., Jermidi, C., Jégou, J., Godet, J., Barra, A., Paris, I., Levillain, P., Cordier-Dirikoc, S., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26355 · Cited by 27
“Tumor development is also delayed in IL-23 or IL-23 receptordeficient mice in various mouse models of cSCC [22].”
BackgroundThe Wnt-Driven Mll1 Epigenome Regulates Salivary Gland and Head and Neck Cancer
Zhu, Q., Fang, L., Heuberger, J., Kranz, A., Schipper, J. H., Scheckenbach, K., Vidal, R. O., Sunaga, D. Y., Müller, M., Wulf-Goldenberg, A., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.059 · Cited by 30
Lactate as a Regulator of Cancer Inflammation and Immunity
dos Santos, N. R., Pereira‐Nunes, A., Baltazar, F., & Granja, S. (2019) · Immunometabolism · doi:10.20900/immunometab20190015 · Cited by 29
“Also, lactic acid secreted by tumor cells activate the IL-23/IL-17 [62,63] proinflammatory pathway but not the Th1 pathway [63].”
BackgroundSender, L. Y., Sutter, K., Suezer, Y., Radeke, H. H., Kalinke, U., & Waibler, Z. (2010) · Molecular Immunology · doi:10.1016/j.molimm.2009.12.008 · Cited by 27
Interleukin-12 Deficiency Is Permissive for Angiogenesis in UV Radiation-Induced Skin Tumors
Meeran, S. M., Katiyar, S., Elmets, C. A., & Katiyar, S. K. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3134 · Cited by 27
“It has been reported that IL-23 promotes tumor incidence and growth and that it is overexpressed in human cancers of various organs (32).”
BackgroundRetractedTian, L., Li, H., Cui, H., Tang, C., Zhao, P., Wang, X., & Cheng, Y. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08101-1 · Cited by 31
“Among these cytokines, TNF could induce the CD4 + CD25 + FoxP3 + Treg differentiation, CSF1 and CCL22 drive the differentiation of F4/80 + CD11b + monocytes to macrophages, and IL-23 inhibited CD8 + T cell in fi ltration and promoted in fl ammation and tumor incidence [28, 29].”
IL-17A-producing T cells and associated cytokines are involved in the progression of gastric cancer
Zhong, F., Cui, D., Hong, T., Du, H., & Xing, C. (2015) · Oncology Reports · doi:10.3892/or.2015.4246 · Cited by 28
Tsuda, K., Yamanaka, K., Kondo, M., Matsubara, K., Sasaki, R., Tomimoto, H., Gabazza, E. C., & Mizutani, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051819 · Cited by 26
“Susceptibility to infection [25] and malignancy [26] has been reported during ustekinumab therapy due to inhibition of IL-12 and IL-23.”
BackgroundPaustian, C. C., Taylor, P., Johnson, T. D., Xu, M., Ramirez, N., Rosenthal, K. S., Shu, S., Cohen, P. A., Czerniecki, B. J., & Koski, G. K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054804 · Cited by 26
Yu, Q., Lou, X., & He, Y. (2013) · Medical Oncology · doi:10.1007/s12032-013-0795-1 · Cited by 30
“In contrast, several reports showed that Th17 cells in solid tumor are involved in tumor promotion or progression [20, 21].”
ResultMalecka, A. A., Wang, Q., Shah, S., Sutavani, R. V., Spendlove, I., Ramage, J. M., Greensmith, J., Franks, H., Gough, M. J., Saalbach, A., et al. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.3a1015-474r · Cited by 26
“IL-23 promotes tumor growth directly and indirectly through Th17 responses that drive proliferation, invasion, metastasis, and angiogenesis [18–23].”
BackgroundImmune mediator expression signatures are associated with improved outcome in ovarian carcinoma
Nakamura, M., Bax, H. J., Scotto, D., Souri, E. A., Sollie, S., Harris, R. J. C., Hammar, N., Walldius, G., Winship, A., Ghosh, S., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1593811 · Cited by 26
Ramos-Vivas, J., Regnault, B., Michel, V., Bussière, F. I., Avé, P., Huerre, M., Labigne-Roussel, A., D’Elios, M. M., & Touati, E. (2008) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463200802100305 · Cited by 27
The Unfolded Protein Response at the Tumor-Immune Interface
Zanetti, M., Su, X., Dosset, M., & Carter, H. K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.823157 · Cited by 27
“Concomitant events include the secretion of tumorpromoting pro-inflammatory cytokines (IL-6, TNFa and IL23) (63, 85) and the production of immune suppressive factors (e.g., Arg1, TGFb, and IDO).”
BackgroundWight, A. E., Sido, J. M., Degryse, S., Ao, L., Nakagawa, H., Qiu, Y., Shen, X., Oseghali, O., Kim, H. J., & Cantor, H. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2200757119 · Cited by 27
Role of T-cell-mediated inflammation in psoriasis: pathogenesis and targeted therapy
Conrad, C., & Flatz (2013) · Psoriasis Targets and Therapy · doi:10.2147/ptt.s26339 · Cited by 36
“27 In addition, blockage of IL-23 but not IL-12 may decrease the long-term risk for malignancies, as IL-23 has been associated with tumor promotion 66 and IL-12 with antitumor and antimetastatic activity.”
Interleukin-23 receptor genetic variants contribute to susceptibility of multiple cancers
Yao, J., Liu, L., & Yang, M. (2013) · Gene · doi:10.1016/j.gene.2013.09.054 · Cited by 24
Tao, Y., Shen, H., Liu, Y., Li, G., Huang, Z., & Liu, Y. (2020) · Carcinogenesis · doi:10.1093/carcin/bgaa058 · Cited by 28
Colorectal Cancer Chemoprevention: A Dream Coming True?
Signorile, M. L., Grossi, V., Fasano, C., & Simone, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087597 · Cited by 28
Interactions between adiposity and genetic polymorphisms on the risk of psoriasis
Li, W., Han, J., Zhang, M.-F., & Qureshi, A. A. (2012) · British Journal of Dermatology · doi:10.1111/bjd.12001 · Cited by 24
Hiwatashi, K., Ueno, S., Sakoda, M., Kubo, F., 立野, 太., Kurahara, H., Mataki, Y., Maemura, K., Ishigami, S., Shinchi, H., et al. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0614-2 · Cited by 26
“TGF-b and IL-23 seem to be important for the maintenance of Th17 cell responses, and Th17 cells has been shown to promote tumor growth and be related to IL-17 expression in a variety cancer tissues.(11) Th17 cells and IL-17 expression are reported to be increased in gastric cancer and associated with clinical stage.”
BackgroundMonk, J. M., Kim, W., Callaway, E. S., Turk, H. F., Foreman, J. E., Peters, J. M., He, W., Weeks, B. R., Alaniz, R. C., McMurray, D. N., et al. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00315.2011 · Cited by 25
Interleukin-23A is associated with tumor growth in Helicobacter-pylori-related human gastric cancer
Liu, C., Zhang, Y., Zhan, J., Zhao, Y., Wan, Q., Peng, H., & Zhu, W. (2014) · Cancer Cell International · doi:10.1186/s12935-014-0104-x · Cited by 24
“IL-23A is involved in the inflammatory response through promoting matrix metalloprotease 9, increasing angiogenesis and reducing CD8 T cells infiltration [3,4].”
BackgroundGöktuna, S. İ., Shostak, K., Chau, T., Heukamp, L. C., Hennuy, B., Duong, H., Ladang, A., Close, P., Klevernic, I. V., Olivier, F., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1473 · Cited by 28
Li, W., Lee, M.-R., Kim, T., Kim, Y. W., & Cho, M.-Y. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.02.084 · Cited by 25
Diagnostic and prognostic value of serum IL-23 in colorectal cancer
El‐Essawi, D. F., Alkady, M. M., & Ibrahim, I. M. (2019) · Arab Journal of Gastroenterology · doi:10.1016/j.ajg.2019.05.002 · Cited by 25
The RAGE/multiligand axis: a new actor in tumor biology
Rojas, A., Schneider, I., Lindner, C., González, I., & Morales, M. A. (2022) · Bioscience Reports · doi:10.1042/bsr20220395 · Cited by 25
Biologic treatment of psoriasis in oncologic patients
Rusiñol, L., Camiña‐Conforto, G., & Puig, L. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2152322 · Cited by 23
“[55] Unknown Unknown Bladder Etanercept, adalimumab Precedent Stability”
BackgroundInfluentialBlauvelt, A., Lebwohl, M., Langley, R. G. B., Rowland, K., Yang, Y., Chan, D., Miller, M. J., You, Y., Yu, J., Thaҫi, D., et al. (2023) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2023.03.035 · Cited by 23
An evidence-based review of skin cancer rates on biologic therapies
Kamangar, F., Neuhaus, I. M., & Koo, J. Y. M. (2011) · Journal of Dermatological Treatment · doi:10.3109/09546634.2011.652064 · Cited by 23
Spontaneous and treatment-induced cancer rejection in humans
Wang, E., Selleri, S., Sabatino, M., Monaco, A., Pós, Z., Worschech, A., Stroncek, D. F., & Marincola, F. M. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.3.337 · Cited by 23
“A recent good example is IL-23 that according to the animal model utilized can either foster or hamper tumor growth [117-122] .”
BackgroundHelper T Cells and Cancer-Associated Inflammation: A New Direction for Immunotherapy?
Dong, C. (2017) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2017.0012 · Cited by 23
Brennan, F. R., Cauvin, A. J., Tibbitts, J., & Wolfreys, A. (2014) · Drug Development Research · doi:10.1002/ddr.21173 · Cited by 23
“…an anti-CD4 mAb in human transgenic mice [Herzyk et al., 2001] or a PDV (Phocine distemper virus) squamous cell carcinoma model used to assess an anti-IL-12/23 mAb [Langowski et al., 2006], can be used to assess the potential of a mAb to suppress host defence against experimental lung metastases.”
BackgroundInfluentialSelected anti-tumor vaccines merit a place in multimodal tumor therapies
Weiss, E., Wunderlich, R., Ebel, N., Rubner, Y., Schlücker, E., Meyer‐Pittroff, R., Ott, O. J., Fietkau, R., Gaipl, U. S., & Frey, B. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00132 · Cited by 25
“The role of Th17 cells in tumor progression and/or regression is under current investigation (Langowski et al., 2006; Hirota et al., 2012; Liu et al., 2012; Middleton et al., 2012).”
BackgroundChoi, S. Y. C., Gout, P. W., Collins, C. C., & Wang, Y. Z. (2012) · Differentiation · doi:10.1016/j.diff.2012.02.005 · Cited by 26
“…(Coles et al., 2011), FOXP3 (encodes a transcription factor which mediates negative regulation of immune suppression) (Josefowicz et al., 2012), IDO1 (IDO1 can induce immune tolerance) (Ferdinande et al., 2012), and IL23A (IL23A can promote tumor incidence and growth) (Langowski et al., 2006).”
BackgroundThe Microbiome and Colorectal Neoplasia: Environmental Modifiers of Dysbiosis
Turner, N. D., Ritchie, L. E., Bresalier, R. S., & Chapkin, R. S. (2013) · Current Gastroenterology Reports · doi:10.1007/s11894-013-0346-0 · Cited by 27
“With respect to adaptive immune system responses to bacteria, it has been demonstrated that barrier defects and microbial products drive CD4 T-helper cell IL-23/IL-17-mediated tumor growth [34, 35].”
BackgroundPsoriasis: Targets and Therapy
Flatz, L., & Conrad, C. (2019) · Psoriasis Targets and Therapy · doi:10.2147/ptt · Cited by 23
Ustekinumab for the Treatment of Crohn‘s Disease
Khanna, R., & Feagan, B. G. (2013) · Immunotherapy · doi:10.2217/imt.13.81 · Cited by 26
Positioning Ustekinumab in Crohn’s Disease: From Clinical Evidence to Clinical Practice
Danese, S., Bonovas, S., & Peyrin‐Biroulet, L. (2017) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjx079 · Cited by 22
RNA m6A modifications regulate crosstalk between tumor metabolism and immunity
Gu, J., Cao, H., Chen, X., Zhang, X. D., Thorne, R. F., & Liu, X. (2023) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1829 · Cited by 24
Self-citationA review on interleukins: The key manipulators in rheumatoid arthritis
Sharma, J., Bhar, S., & Devi, C. S. (2017) · Modern Rheumatology · doi:10.1080/14397595.2016.1266071 · Cited by 22
“STAT3 signaling in tumor niche can upregulate IL-23 production, which leads to more carcinogenesis [340,341].”
BackgroundThe molecular basis of chaperone-mediated interleukin 23 assembly control
Meier, S., Bohnacker, S., Klose, C. J., López, A., Choe, C. A., Schmid, P. W. N., Bloemeke, N., Rührnößl, F., Haslbeck, M., Bieren, J. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12006-x · Cited by 22
Akazawa, T., Inoue, N., Shime, H., Kodama, K., Matsumoto, M., & Seya, T. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01583.x · Cited by 22
Qian, X., Cao, S., Yang, G., Pan, Y., Yin, C., Chen, X., Zhu, Y., Zhuang, Y., Shen, Y., & Hu, Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055473 · Cited by 21
IL-23 Blockade for Crohn s disease: next generation of anti-cytokine therapy
Furfaro, F., Gilardi, D., Allocca, M., Cicerone, C., Correale, C., Fiorino, G., & Danese, S. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1279055 · Cited by 23
“It also appears that IL23 is a potent tumor-promoting factor and elevated levels have been described in human colorectal tumors [36].”
BackgroundLinton, A. E., Weekman, E. M., & Wilcock, D. M. (2021) · Cerebral Circulation - Cognition and Behavior · doi:10.1016/j.cccb.2021.100030 · Cited by 22
“The mechanism of action of MMP9 in the context of tumor metastasis remains undefined but it is hypothesized that it induces invasion and migration through its interaction with angiogenic agents [69].”
BackgroundFeng, B., Pan, B., Huang, J., Du, Y., Wang, X., Wu, J., Ma, R., Shen, B., Huang, G., & Feng, J. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216224 · Cited by 23
Jung, J. M., Kim, Y., Chang, S. E., Lee, M. W., Won, C. H., & Lee, W. J. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05387-6 · Cited by 22
“The key role of IL-12 and IL-23 in developing of antitumor and protumor immunity, respectively, has been described (Dunn et al. 2006; Langowski et al. 2006).”
BackgroundTGFβ1-Induced Inflammation in Premalignant Epidermal Squamous Lesions Requires IL-17
Mohammed, J., Ryscavage, A. O., Pérez‐Lorenzo, R., Gunderson, A. J., Blazanin, N., & Glick, A. B. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.92 · Cited by 23
“, 2007), and both IL-17 and IL-23 can induce proinflammatory and proangiogenic cytokines (Jovanovic et al., 1998; Kolls and Linden, 2004; Langowski et al., 2006) that could promote tumor growth and progression.”
BackgroundNew insights into tumor dormancy: Targeting DNA repair pathways
Evans, E. B., & Lin, S.-Y. (2015) · World Journal of Clinical Oncology · doi:10.5306/wjco.v6.i5.80 · Cited by 22
Zhang, Y., Wang, J., Wang, W., Tian, J., Yin, K., Tang, X., Ma, J., Xu, H., & Wang, S. (2016) · Tumor Biology · doi:10.1007/s13277-016-5414-2 · Cited by 23
Cutrona, G., Tripodo, C., Matis, S., Recchia, A. G., Massucco, C., Fabbi, M., Colombo, M., Emionite, L., Sangaletti, S., Gulino, A., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aal1571 · Cited by 21
Innate lymphoid cells: A potential link between microbiota and immune responses against cancer
Panda, S. K., & Colonna, M. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.03.003 · Cited by 23
Innate Lymphoid Cells in Colorectal Cancers: A Double-Edged Sword
Huang, Q., Cao, W. H. J., Mielke, L. A., Seillet, C., Belz, G. T., & Jacquelot, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03080 · Cited by 21
Ni, B., Chen, S., Xie, H., & Ma, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089111 · Cited by 21
“Moreover, previous studies have indicated that IL23R can promote tumor growth and may decrease immunosurveillance by CD8 T-cells [11].”
BackgroundIEX-1 Deficiency Protects against Colonic Cancer
Ustyugova, I. V., Liang, Z., Abramowitz, J., Birnbaumer, L., & Wu, M. X. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0556 · Cited by 21
“Moreover, elevated levels of IL17A as well as TH17 cells were found in various tumors (28, 29, 30, 31, 32).”
BackgroundDefective IL-23/IL-17 Axis Protects p47phox−/− Mice from Colon Cancer
Richter, C., Juan, M. H. S., Weigmann, B., Bergis, D., Dauber, K., Muders, M. H., Baretton, G. B., Pfeilschifter, J. M., Bonig, H. B., Brenner, S., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00044 · Cited by 23
“Human data have been confirmed in tumor models of mice (12, 16, 17).”
BackgroundInfluentialDao, V. A., Pandeswara, S., Liu, Y., Hurez, V. J., Dodds, S. G., Callaway, D. A., Liu, A., Hasty, P., Sharp, Z. D., & Curiel, T. J. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-14-0313-t · Cited by 20
“2E), a concentration that does not inhibit proliferation of a skin cancer cell line or other cancer cell lines in vitro (data not shown). eRapa protection does not require suppression of known proinflammatory factors or significant reductions in keratinocyte stem cell numbers, proliferation, or epidermal hyperplasia I…”
BackgroundInfluentialGenetic variability in IL23R and risk of colorectal adenoma and colorectal cancer
Poole, E. M., Curtin, K., Hsu, L., Duggan, D. J., Makar, K. W., Xiao, L., Carlson, C. S., Caan, B. J., Potter, J. D., Slattery, M. L., et al. (2011) · Cancer Epidemiology · doi:10.1016/j.canep.2011.11.001 · Cited by 20
“IL-23 p19 mRNA was upregulated in 36 human colorectal cancer tissue samples compared to paired adjacent normal tissue [3].”
BackgroundMeng, Q., Wu, S., Wang, Y., Xu, J., Sun, H., Lu, R., Gao, N., Yang, H., Li, X., Tang, B., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2538 · Cited by 21
“Previous study have showed that IL-23A promotes tumor incidence and growth by targeting MMP9(20).”
BackgroundCorrelation of miR-425-5p and IL-23 with pancreatic cancer
Lu, Y., Wu, X., & Wang, J. (2019) · Oncology Letters · doi:10.3892/ol.2019.10099 · Cited by 23
“In the study of Langowski et al (13), IL-23 was found to play a role in promoting tumor growth in mice deficient in IL-23p19 (one of two subunits of IL-23). miR-425-5p and IL-23 have rarely been studied in clinical aspects of pancreatic cancer.”
BackgroundMa, H., Cao, L., Wang, F., Cheng, C., Jiang, R., Zhou, H., Xie, Z., Wuermanbieke, S., & Qian, Z. (2020) · Oncology Reports · doi:10.3892/or.2020.7532 · Cited by 25
“IL23A associates with interleukin 12B to form interleukin (IL)-23, a heterodimeric cytokine which induces autoimmune inflammation, and is related to tumor incidence and growth (34).”
BackgroundRevisiting lactate dynamics in cancer—a metabolic expertise or an alternative attempt to survive?
Mendes, C., & Serpa, J. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01965-0 · Cited by 20
“mours, including colon, breast, and gastric carcinomas and melanoma [195].”
BackgroundHou, C., Lu, L., Liu, Z., Lian, Y., & Xiao, J. (2021) · FEBS Open Bio · doi:10.1002/2211-5463.13230 · Cited by 20
“It has been reported that IL-23 can mediate inflammatory processes providing a tumor microenvironment by activating the signal transducer and activator of transcription 3 (STAT3) signaling pathway in tumors[12, 13].”
BackgroundSong, N., Li, X., Ma, B., Willette‐Brown, J., Zhu, F., Jiang, C., Su, L., Shetty, J., Zhao, Y., Shi, G., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2120956119 · Cited by 20
“IL-23A inhibits CD8 T cell infiltration, enhances inflammation, and increases tumor incidence (26, 27), and ADAM8 promotes cell proliferation, invasion, and metastasis in human cancers (28, 29).”
BackgroundChakraborty, K., Chatterjee, S., & Bhattacharyya, A. (2014) · International Immunopharmacology · doi:10.1016/j.intimp.2014.02.015 · Cited by 20
“IL-23, a member of the IL-12 family, is composed of the p40 subunit in common with IL-12, paired with a unique p19 subunit [28,34] which showed decreased tumorigenesis in IL-23/ p19KO mice and increased tumorigenesis in IL-12/p35 KO mice.”
BackgroundCancer: evolutionary, genetic and epigenetic aspects
Lichtenstein, A. V. (2010) · Clinical Epigenetics · doi:10.1007/s13148-010-0010-6 · Cited by 21
IL-23R is Epigenetically Regulated and Modulated by Chemotherapy in Non-Small Cell Lung Cancer
Baird, A., Dockry, É., Daly, A. K., Stack, E., Doherty, D. G., O'Byrne, K. J., & Gray, S. G. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00162 · Cited by 20
“It has been shown that IL-23 provides a connection between the pro-inflammatory processes which promote tumor growth and the failure of adaptive immune mediators to penetrate tumors (Langowski et al., 2006; Langowski et al., 2007).”
BackgroundInfluential
Metadata
- Authors
- Langowski, J. L., Zhang, X., Wu, L., Mattson, J. D., Chen, T., Smith, K., Basham, B., McClanahan, T., Kastelein, R. A., & Oft, M.
- Corresponding author
- Oft, Martin
- Venue
- Nature
- Published
- 2006-05-10
- Volume
- 442
- Issue
- 7101
- Pages
- 461-465
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1984467626
- Cited by
- 1,018
- References
- 30
- Citations by year
- 2026: 23 · 2025: 18 · 2024: 32 · 2023: 46 · 2022: 42 · 2021: 44 · 2020: 41 · 2019: 52 · 2018: 41 · 2017: 41 · 2016: 41 · 2015: 47 · 2014: 62 · 2013: 72 · 2012: 65
- FWCI
- 24.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- IL-23, tumour-associated inflammation, tumor surveillance, CD8+ T cell infiltration, intraepithelial lymphocytes, tumor microenvironment, angiogenesis, MMP-9, IL-12, chemical carcinogenesis, IL23R, tumor growth, cancer immunotherapy
- MeSH terms
- Animals, Cell Division, Humans, Inflammation, Interleukins, Mice, Inbred C57BL, Neoplasms, Signal Transduction, CD8-Positive T-Lymphocytes, Interleukin-12, Genetic Predisposition to Disease, Mice, Interleukin-23, Interleukin-23 Subunit p19
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.